Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Serrano
D
D
Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. davide.serrano@ieo.it
Lazzeroni
M
M
Zambon
C-F
CF
Macis
D
D
Maisonneuve
P
P
Johansson
H
H
Guerrieri-Gonzaga
A
A
Plebani
M
M
Basso
D
D
Gjerde
J
J
Mellgren
G
G
Rotmensz
N
N
Decensi
A
A
Bonanni
B
B
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D015239:Arylsulfotransferase / Q000235:genetics; D001943:Breast Neoplasms / Q000517:prevention & control*; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D007558:Italy; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human